RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Brief Description

The KIND study is testing the safety, efficacy, and pharmacokinetics of paricalcitol oral solution in participants of ages 0 to 9 years that have been diagnosed with Secondary Hyperparathyroidism (SHPT) associated with stage 5 Chronic Kidney Disease (CKD) receiving Peritoneal Dialysis (PD) or Hemodialysis (HD).

Trial Physician / Study Coordinator

Cat Justice

Estimated Enrollment

16 patients

Estimated End Date

February 2027

Trial is for people with

2-9 years old patients diagnosed with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) stage 5 receiving ...

Study Goal

The goal of the study is to assess the effect of Paracalcitol on blood calcium levels and intact parathyroid hormone (iPTH) in ...

What is involved for the patient?

Participants will be administered paricalcitol three times a week (TIW) but no more frequently than every other day for 24 weeks.

About the drug or intervention

Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser.

Find other locations for this trial:
Philadelphia, PA

I'm Interested in this Trial

"*" indicates required fields

Your name*
This field is hidden when viewing the form
Your contact information will be sent to a team at
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
Have you ever had a kidney transplant?*
Are you currently on dialysis?*
Did you have a biopsy to confirm your diagnosis?*
Are you currently on the transplant wait-list?*
This field is hidden when viewing the form
This field is hidden when viewing the form
Interested in CT
Disclaimer

By clicking the submit button, your information and results will be sent to the study coordinator. Submitting the form does not guarantee enrollment but helps determine potential eligibility and connects you with the study team. Please consult your healthcare provider before pursuing participation in any trial.

Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

Clinical studies are any studies that involve people. There are two main types: observational and interventional. In an observational trial, researchers track health outcomes over time in groups of participants to look for patterns that help us better understand a disease. In an interventional trial, participants receive specific interventions, which can include new treatments or behavorial changes (e.g., diet changes). To learn more about clinical research, please visit the NephCure website.

See other frequently asked questions